OrbiMed’s Theseus Pharmaceuticals, Inc. Common Stock THRX Stock Holding History

OrbiMed’s Portfolio THRX Stock Details THRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-17,713,600	Closed	-$71.7M	–	132
2023 Q4	$71.7M	Hold	17,713,600	–	–	1.43%	24
2023 Q3	$47.6M	Buy	17,713,600 +479,932	+3%	+$1.88M	1.01%	36
2023 Q2	$161M	Hold	17,233,668	–	–	2.91%	5
2023 Q1	$153M	Hold	17,233,668	–	–	3%	8
2022 Q4	$85.8M	Buy	17,233,668 +192,000	+1%	+$1.12M	1.64%	16
2022 Q3	$98.8K	Hold	17,041,668	–	–	1.83%	19
2022 Q2	$94.2K	Hold	17,041,668	–	–	1.71%	22
2022 Q1	$196M	Buy	17,041,668 +203,000	+1%	+$2.17M	3.19%	5
2021 Q4	$214M	Buy	+16,838,668	New	+$254M	2.74%	5

OrbiMed's THRX Position: Q1 2024 in Review

OrbiMed sold out of Theseus Pharmaceuticals, Inc. Common Stock (THRX) in Q1 2024, closing a stake of 17,713,600 shares — an estimated $71.7M sold.

OrbiMed first reported a position in THRX in Q4 2021 and held it in 9 quarters. The position peaked at $214M in Q4 2021. 1 fund tracked by Wall St. Rank holds THRX as of Q1 2024.

OrbiMed reported no remaining Theseus Pharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
OrbiMed sold 17,713,600 Theseus Pharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $71.7M.
OrbiMed first reported a position in Theseus Pharmaceuticals, Inc. Common Stock in Q4 2021 and held it in 9 quarters.
OrbiMed's Theseus Pharmaceuticals, Inc. Common Stock position peaked at $214M in Q4 2021.
1 fund tracked by Wall St. Rank held Theseus Pharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on OrbiMed's 13F filing for Q1 2024, filed 15 May 2024.